pages:
-
A Phase III, Open Label, Multicenter Trial to Evaluate Ejection Fraction, End Diastolic and End Systolic Volumes, by Unenhanced and DEFINITY enhanced 2D-Echo and Magnetic Resonance Imaging
-
A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza¿) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Canc
-
A Phase III, Open Label,Extension Trial of ECU-MG-301 to evaluate the Safety and Efficacy of Eculizumab in subjects with Refractory Generalized Myasthenia Gravis
-
A PHASE III, OPEN-LABEL, EXTENSION TRIAL OF ECU-NMO-301 TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA (NMO)
-
A Phase III, open-label, multi-center, randomized study to investigate the efficacy and safety of MPDL3280A
-
A Phase III, Open-Label, Multicenter Trial to Evaluate Ejection Fraction, End-Diastolic and End-Systolic Volumes, by Unenhanced and DEFINITY®-enhanced 2D-Echo and Magnetic Resonance Imaging
-
A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF GLOFITAMAB IN COMBINATION WITH GEMCITABINE
-
A Phase III, Randomized, Double-blind Study to Evaluate
Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as
Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant
Therapy for Triple Negative Breast Cancer (TNBC
-
A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo asFirst-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Juncti
-
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
-
A Phase III, randomized, double-blind, placebo-controlled study of AeroVanc for the treatment of persistent methicillin-resistant Staphylococcus aureus lung infection in cystic fibrosis patients
-
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin (G+C) for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treat
-
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer
-
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Studyof Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellula
-
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-ARM, MULTI-CENTER STUDY MEASURING THE EFFICACY AND SAFETY OF PRC-063 IN ADOLESCENT ADHD PATIENTS
-
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-ARM, MULTI-CENTER STUDY MEASURING THE EFFICACY AND SAFETY OF PRC-063 IN ADULT ADHD PATIENTS
-
A Phase III, Randomized, Multi-Center, Open-Label, Active-Comparator Controlled Study To Evaluate the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
-
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MeRmaiD-1)
-
A PHASE IIIb OPEN-LABEL, SINGLE-ARM STUDY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TO EVALUATE THE USABILITY OF RANIBIZUMAB 10 mg/0.1 mL PREFILLED SYRINGE WITH THE PORT DELIVERY SYSTEM
Research Grant
-
A phase IIIb, open-label, multicenter study to evaluate the safety of 1.0mg/kg subcutaneously administered Efalizumab ...
Fellowships, Supported Research, and Other Grants
-
A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in
Participants with Advanced Malignancies
Research Grant
-
A Phase IV open-label study to evaluate the safety and efficacy of 1mg/kg SQ administered efaluzimab in adults with bullous pemphigoid as a steroid sparing adjunctive treatment
Fellowships, Supported Research, and Other Grants
-
A Phase lll Multi-Center, Randomized, Open-label,
Comparative Study to Assess the Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Patients with Intravenous Catheter-Associated Bloodstream Infections (BSI) due to Staphylococci
-
A phase-2, multicenter, randomized, double-blinded, placebo-controlled, parallel-group, efficacy and safety study of apremilast (CC10004) in subjects with moderate to severe atopic dermatitis
Fellowships, Supported Research, and Other Grants
-
A phase3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination for 12 weeks in Subjcts with Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
-
A PHASEIB/III STUDY OF IPATASERTIB PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN HORMONE RECEPTOR POSITIVE AND HER2 NEGATIVE LOCALLY ADVANCED UNRESECTABLE OR METASTATIC BREAST CANCER
-
A Photochemically 3D Printed High-Resolution Biodegradable Suture Retention Clip
Research Grant
-
A Pilot Intervention Study on Depressive Symptoms of Midlife Korean American
Fellowships, Supported Research, and Other Grants
-
A Pilot Study in Healthy Male Volunteers to Evaluate a Skeletal-muscle Microbiopsy Technique
-
A Pilot Study in Human Subjects Evaluating the Use of the NanoKnife System for Ablation of Prostate Cancer Tissue in a Low Risk Patient Population
pages: